Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Clinical trial NCT06231680 · UNKNOWN
Trial details
- NCT number
- NCT06231680
- Sponsor
- Henan Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-19
- Primary completion
- 2024-06-30
- Enrollment
- 132
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.